Panelists discuss recent phase 3 trials introducing novel endocrine agents such as proteolysis-targeting chimeras (PROTACs) ...

Panelists discuss the SERENA-6 trial evaluating camizestrant, which uniquely enrolled patients with molecularly detected ESR1 ...

Two glioblastoma patients treated with Temferon have lived 3 years post-surgery; one had no progression, the other stabilized ...

Metformin use may enhance progression-free survival (PFS) in patients receiving first-line systemic therapy for patients with ...

Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...

The combination of cabozantinib and atezolizumab appeared more effective than switching ARPI therapy in patients with mCRPC and extrapelvic soft-tissue metastases.

The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a ...

Adding ibrutinib to rituximab improved outcomes in patients with previously untreated FL who were ineligible for CIT.

Colorectal cancer (CRC) is the second most common cause of death from cancer in the US and the most prevalent malignant tumor ...

Significantly longer progression-free and overall survival seen in patients with BRAF V600E mutations.

Progression-free survival at 5 years was 93.9% with ibrutinib–venetoclax, 79.0% with ibrutinib alone, and 58.1% with FCR.